Extracellular vesicles from embryonic stem cells successfully reversed chemotherapy-induced ovarian failure in mice, restoring estrous cycles, fertility, and follicle counts while reducing fibrosis and senescence markers. The treatment reactivated key fertility genes including Figla, Nobox, Gdf9, and Bmp15, and modulated Nrf2 and DNA damage response pathways in granulosa cells. This represents a potential breakthrough in reproductive medicine, offering hope for women facing fertility loss from cancer treatments. The cell-free approach sidesteps ethical concerns around stem cell therapy while targeting the fundamental aging processes that drive ovarian decline. However, the mouse model limitations are significant—human ovarian aging involves complex hormonal and metabolic factors not fully captured in chemotherapy-induced damage. The safety profile of ESC-derived vesicles remains unclear, particularly regarding their contents and potential immunogenicity. While promising for fertility preservation, this approach may have broader anti-aging implications given its ability to reverse tissue senescence and fibrosis, hallmarks of aging across multiple organ systems. The findings warrant cautious optimism pending human safety trials.